Bernd Seizinger Purchases 60,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger purchased 60,000 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was bought at an average price of $0.83 per share, with a total value of $49,800.00. Following the completion of the transaction, the director owned 526,991 shares of the company’s stock, valued at $437,402.53. This represents a 12.85% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Oncolytics Biotech Price Performance

ONCY opened at $1.06 on Friday. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51. The firm has a market capitalization of $112.51 million, a P/E ratio of -3.79 and a beta of 0.99. The company has a fifty day moving average price of $0.98 and a 200-day moving average price of $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. On average, analysts expect that Oncolytics Biotech Inc. will post -0.28 earnings per share for the current year.

Oncolytics Biotech News Summary

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Institutional Investors Weigh In On Oncolytics Biotech

Several hedge funds and other institutional investors have recently modified their holdings of the business. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Oncolytics Biotech during the fourth quarter valued at $29,000. Tocqueville Asset Management L.P. purchased a new stake in Oncolytics Biotech in the 4th quarter valued at about $63,000. CIBC Private Wealth Group LLC bought a new position in Oncolytics Biotech in the 4th quarter worth about $44,000. Ground Swell Capital LLC bought a new position in Oncolytics Biotech in the 4th quarter worth about $30,000. Finally, Scientech Research LLC purchased a new position in shares of Oncolytics Biotech during the third quarter worth approximately $25,000. 6.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ONCY shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. HC Wainwright lifted their price objective on Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Wall Street Zen lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $6.25.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.